[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vitamin-d-concentration\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vitamin-d-concentration":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,58,90],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100650313","vitamin-d-status-and-clinical-outcomes-in-locally-advanced-cervical-cancer-100650313",false,"NCT07743918","Vitamin D Status and Clinical Outcomes in Locally Advanced Cervical Cancer","Pretreatment Vitamin D Status and Clinical Outcomes in Patients With Locally Advanced Cervical Cancer Undergoing Definitive Chemoradiotherapy","CERVITAL","Inclusion Criteria:\n\n* Female patients aged 18 to 80 years.\n* Histopathologically confirmed cervical cancer.\n* Locally advanced disease, FIGO 2018 stage IIB to IVA.\n* Eastern Cooperative Oncology Group performance status 0-1.\n* Planned treatment with definitive concurrent chemoradiotherapy.\n* Signed informed consent.\n* Ability to comply with study procedures and follow-up visits.\n\nExclusion Criteria:\n\n* Age under 18 years.\n* Pregnancy or lactation.\n* Previous or synchronous diagnosis of another pelvic or abdominal malignancy.\n* Previous chemotherapy.\n* Previous radiotherapy.\n* Previous treatment with immune checkpoint inhibitors.\n* Current or recent vitamin D supplementation.\n* Interrupted oncological treatment.\n* Failure to attend scheduled follow-up visits.\n* Incomplete medical documentation.","FEMALE","18 Years","80 Years",{"count":21,"type":22},100,"ESTIMATED","7 Months","OBSERVATIONAL","Background. Definitive chemoradiotherapy represents the standard therapeutic approach for the management of locally advanced cervical cancer. Vitamin D plays an important role in the regulation of cellular growth and differentiation, immune system function, and the modulation of inflammatory processes. Hypovitaminosis D may be associated with the development of cervical cancer, whereas its impact on the effects of oncological treatment remains insufficiently elucidated. The aim of this study is to investigate the predictive significance of vitamin D in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy.\n\nMethods. This study is designed as a clinical, observational, prospective cohort study. Patients with locally advanced cervical cancer undergoing definitive chemoradiotherapy at the Clinic for Radiation Oncology, University Clinical Center Kragujevac, will be enrolled. Vitamin D concentrations will be measured before the initiation of treatment in both serum and cervical lavage samples. Baseline vitamin D levels will be analyzed in relation to treatment outcome and the occurrence of acute radiation toxicity. In addition, vitamin D concentrations will be evaluated in the context of clinical and morphological parameters, therapeutic response, and treatment-related toxicity.\n\nExpected Results. This study will enable an assessment of the actual significance of pretreatment vitamin D concentrations in serum and cervical lavage as a potential novel biomarker in relation to chemoradiosensitivity and\u002For chemoradioresistance of cervical cancer, as well as the response of organs at risk, in patients with locally advanced disease.",[27,28],"Locally Advanced Cervical Cancer","Vitamin D Concentration",[30,31,32,33,34,35,36,37,38,39,40,41,42,43,44],"Locally advanced cervical cancer;","vitamin D;","hypovitaminosis D;","serum vitamin D;","cervical lavage;","chemoradiotherapy;","radiotherapy;","cisplatin;","brachytherapy;","treatment response;","radiation toxicity;","RECIST 1.1;","CTCAE;","chemoradiosensitivity;","chemoradioresistency","RECRUITING","2026-07-31",{"date":48,"type":49},"2026-08-04","ACTUAL",{"date":51,"type":49},"2026-01-01",{"date":53,"type":22},"2034-09-01",{"name":55,"class":56},"University of Kragujevac","OTHER",1,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":4,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":65,"enrollmentInfo":66,"targetDuration":4,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":76,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":57},"100619810","cardioprotective-effect-of-melatonin-versus-vitamin-d-in-breast-cancer-patients-receiving-doxorubicin-100619810","NCT07349459","Cardioprotective Effect of Melatonin Versus Vitamin D in Breast Cancer Patients Receiving Doxorubicin","Clinical Study Evaluating Cardioprotective Effect of Melatonin Versus Vitamin D in Breast Cancer Patients Receiving Doxorubicin","Inclusion Criteria:\n\n* Age from 18 to 65 years old.\n* Gender: female.\n* Positive breast cancer women who are scheduled to receive Doxorubicin.\n* Have a good performance status according to the eastern cooperative oncology group with a score of 0-2.\n* Normal baseline Echocardiography with left ventricular ejection fraction ≥ 50%.\n* Normal renal and liver function tests.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women.\n* Women with HER-2 positive of breast cancer.\n* Formerly treated with Doxorubicin.\n* Patients with a known hypersensitivity to any of the used drugs.\n* On other concomitant vitamins or food supplements.\n* Valvular heart disease, coronary artery disease, history of congestive heart failure or cardiomyopathy.\n* Impaired Left ventricular systolic function in which the Left Ventricular Ejection Fraction \\\u003C 50%.","65 Years",{"count":67,"type":22},90,"INTERVENTIONAL",[70],"NA","This study aims to assess the cardioprotective effect of melatonin and vitamin D in breast cancer patients who receive doxorubicin.",[73,74,28,75],"Melatonin","Breast Cancer Patients Diagnosed","Doxorubicin",[77,75,78,73,79],"Vitamin D","Cardioprotective Effect","Breast Cancer Patients","NOT_YET_RECRUITING","2026-01-09",{"date":83,"type":49},"2026-01-16",{"date":85,"type":22},"2026-04-30",{"date":87,"type":22},"2026-08-30",{"name":89,"class":56},"Tanta University",{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":97,"sex":98,"minAge":18,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":4},"100604210","vitamin-d-satus-in-adults-with-newly-diagnosed-itp-100604210","NCT07146555","Vitamin D Satus in Adults With Newly Diagnosed ITP","Evaluation of Vitamin D Status in Adult Patients With Newly Diagnosed Immune Thrombocytopenia (ITP)","Inclusion Criteria:1- Adult (age\\>18 years) 2-Primary ITP. 3-Patients with ITP who received first line steroid therapy.\n\nExclusion Criteria:1-Age less than18years 2-Secodary ITP 3-Patients with ITP on second line steroid therapy. 4-Chronic renal disease. 5-Chronic liver disease. 6-Malnutrition and malabsorption.",true,"ALL","50 Years",{"count":101,"type":22},84,"Investigator study aims to assess the level of vitamin D in adult patients with newly diagnosed ITP and correlation between its level and treatment respose",[28],"2025-08-30",{"date":106,"type":49},"2025-09-08",{"date":108,"type":22},"2025-09-30",{"date":110,"type":22},"2027-10-30",{"name":112,"class":56},"Assiut University"]